Guardant Health Appoints Craig Eagle, MD as Chief Medical Officer

May 3, 2021

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announces the appointment of Craig Eagle, MD as the company’s new Chief Medical Officer (CMO).

This press release features multimedia. View the full release here:

Dr. Craig Eagle, MD (Photo: Business Wire)

Dr. Craig Eagle, MD (Photo: Business Wire)

As CMO, Dr. Eagle will play a vital role in furthering Guardant Health’s mission of transforming cancer care by unlocking data that will accelerate precision oncology for patients at all stages of the disease. “I am thrilled to welcome Dr. Craig Eagle, a respected leader in oncology, as our Chief Medical Officer,” said AmirAli Talasaz, Guardant Health President. “Craig has a wealth of experience driving medical affairs, clinical development, and clinical trial operations at leading pharmaceutical companies, and he will undoubtedly make a great impact as we continue to develop and commercialize first-in-class products and scale the company for the future.”

“I look forward to contributing to the ground-breaking work Guardant Health is doing to serve unmet medical needs by applying precision oncology across the continuum of cancer care,” said Craig Eagle, MD. “Guardant Health is uniquely positioned to serve cancer patients at all stages of the disease, from advanced to early-stage cancers. I look forward to joining the team as the company continues to increase patient access to potentially life-changing diagnostics and testing.”

Prior to joining Guardant Health, Dr. Eagle has most recently served as Vice President of Medical Affairs Oncology for Genentech where he oversaw the medical programs across the oncology portfolio, and developed innovative cancer trials and strategies in personalized health care. Prior to Genentech, Dr. Eagle has held several positions in the U.S. and internationally over his 19-year career at Pfizer including global head of the Oncology Medical and Outcomes Group. In this role, he oversaw the worldwide medical programs and development of numerous commercially successful drugs. Dr. Eagle currently serves on the Board of Directors for Generex Biotechnology and NuGenerex Immuno-Oncology.

Dr. Eagle attended medical school at the University of New South Wales in Sydney, Australia and received his general internist training at Royal North Shore Hospital in Sydney. Dr. Eagle completed his specialist training in hemato-oncology and laboratory hematology at Royal Prince Alfred Hospital in Sydney and was granted Fellowship in the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists Australasia (FRCPA).

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Revealtest for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential scope, impact or benefit of Guardant Health liquid biopsies which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2020 as well as in its other reports filed with the Securities and Exchange Commission, including, when filed, its Quarterly Report on Form 10-Q for the period ended March 31, 2021. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

Source: Guardant Health, Inc.

Investor Contact:
Carrie Mendivil

Media Contact:
Anna Czene

Julie Johnson

Source: Guardant Health, Inc.